小鼠 体内 腹膜腔组织驻留巨噬细胞高效基因和 MicroRNA 调控的慢病毒载体制备
February 16th, 2024
2K views
我们展示了使用慢病毒载体在 体内研究腹膜组织驻留巨噬细胞基因功能的分步方案。
与巨噬细胞体内基因操作的其他病毒方法相比，使用慢病毒载体提供了转基因组织巨噬细胞的稳定整合、高效的转基因表达和最大的载体大小限制。当采用代谢酶的体内慢病毒操作时，我们发现组织驻留巨噬细胞的显着功能变化。因此，我们目前正在研究免疫代谢及其在保持组织特异性功能（包括表观遗传学和免疫功能）中的作用。
未来，我们希望专注于定义组织巨噬细胞在稳态期间和疾病模型中如何影响其他局部细胞群，以及如何利用这些相互作用来预防和解决疾病。
概述
本研究提出了一种详细的方案，用于使用慢病毒载体在体内研究腹膜组织中驻留巨噬细胞的基因功能。使用慢病毒载体可实现基因稳定整合和巨噬细胞中高效的转基因表达。
关键研究组成部分
科学领域
- 神经科学
- 免疫学
- 基因治疗
背景
- 慢病毒载体提供了转基因的稳定整合。
- 它们对巨噬细胞的体内基因操作非常有效。
- 了解巨噬细胞的功能对于研究免疫反应至关重要。
- 研究免疫代谢可以揭示组织特异性功能的洞见。
研究目的
- 探索组织中驻留巨噬细胞在基因功能中的作用。
- 评估代谢酶对巨噬细胞功能的影响。
- 研究巨噬细胞与局部细胞群之间的相互作用。
使用的方法
- 在受控环境中制备慢病毒组件。
- 混合溶液以确保病毒载体的适当整合。
- 体内操作巨噬细胞以研究基因功能。
- 评估操作后巨噬细胞的功能变化。
主要结果
- 观察到组织中驻留巨噬细胞的显著功能变化。
- 通过这种方法获得了免疫代谢方面的洞见。
- 该研究为未来研究巨噬细胞相互作用奠定了基础。
- 识别了预防和解决疾病的潜在应用。
结论
- 慢病毒载体对于研究巨噬细胞中的基因功能是有效的。
- 了解巨噬细胞的行为可以为治疗策略提供信息。
- 未来的研究将集中在健康和疾病中的巨噬细胞相互作用。
常见问题
什么是慢病毒载体？
慢病毒载体是用于将遗传物质递送到细胞中的工具，允许稳定的基因表达。
为什么要研究组织中驻留的巨噬细胞？
组织中驻留的巨噬细胞在免疫反应和组织稳态中扮演着关键角色。
什么是免疫代谢？
免疫代谢指的是研究代谢过程如何影响免疫细胞功能的学科。
基因操作如何影响巨噬细胞？
基因操作可以导致巨噬细胞的功能变化，影响它们在免疫中的角色。
这项研究暗示了哪些未来方向？
未来的研究可能会探索巨噬细胞与各种疾病模型中的其他细胞类型的相互作用。
Executive Industry Relevance
Lentiviral vector-mediated gene and microRNA modulation in peritoneal tissue-resident macrophages enables rapid, in vivo functional interrogation of immune cell pathways within their physiological niche. This approach supports predictive confidence in target validation and mechanistic de-risking at the discovery stage, particularly for immunometabolic and epigenetic targets. The protocol's efficiency and specificity facilitate risk-adjusted portfolio decisions for immune modulation strategies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct hypothesis testing of gene and microRNA function in tissue-resident macrophages in vivo.
- Supports mechanistic de-risking by clarifying immune pathway contributions to tissue homeostasis and pathology.
- Facilitates functional target validation in both homeostatic and inflammatory states.
- Provides rapid assessment of gene function without reliance on whole-animal transgenic models.
Screening & Assay Development
- Prepares validated in vivo models for downstream screening of immune-modulating compounds.
- Delivers reproducible and quantifiable transgene expression in target macrophage populations.
- Enables standardization of infection rates and transgene dose-response relationships.
- Supports scalable preparation of lentiviral vectors for repeated or parallel studies.
Translational & Preclinical Research
- Aligns with disease-relevant models by enabling gene modulation during both homeostasis and induced peritonitis.
- Provides continuity from discovery through preclinical validation of immune targets.
- Supports translational biomarker development by enabling in vivo readouts of macrophage function.
- De-risks advancement of immune-modulating strategies by clarifying tissue-specific effects.
Pipeline & Workflow Integration
This protocol integrates at the interface of early discovery and preclinical research, bridging target validation and functional screening in immune cell populations.
- Discovery Biology: Supports hypothesis-driven testing of gene and microRNA roles in macrophage biology.
- Screening: Provides quantitative infection and expression metrics for assay readiness.
- Analytics: Enables measurement of infection rates, transgene expression intensity, and time-course persistence in vivo.
- Translational Research: Connects in vivo macrophage modulation to disease-relevant models and biomarker strategies.
- Enterprise Reuse: Offers a reusable platform for rapid gene function assessment across immune targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in immune target validation and reduces mechanistic ambiguity.
- Operational Value: Standardizes in vivo gene modulation with high reproducibility and infection efficiency.
- Strategic Value: Accelerates go/no-go decisions and reduces reliance on time-intensive transgenic models.
- Portfolio Impact: Enables risk-adjusted prioritization of immune-modulating assets based on in vivo functional data.
Implementation Considerations
- Requires expertise in lentiviral vector preparation and in vivo delivery techniques.
- Needs access to ultracentrifugation and fluorescence-based analytical infrastructure.
- Demands cross-team standardization of infection protocols and readout metrics.
- Adaptation may be needed for other tissue-resident macrophage populations or disease models.
- Protocol limitations include transient infection duration and low-level inflammation from intraperitoneal delivery.
Biopharma FAQs
Why does null hypothesis testing matter for lentiviral gene modulation in macrophages?
Null hypothesis testing enables rigorous evaluation of whether observed functional changes in peritoneal macrophages are attributable to specific gene or microRNA modulation, supporting confident target validation in immune discovery pipelines.
How does independent variable isolation fit the lentiviral infection workflow?
By restricting lentiviral infection to peritoneal macrophages and controlling for dose and timing, the protocol isolates the effects of specific genetic modifications, clarifying causal relationships in immune function studies.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative readouts such as infection rate, mean fluorescent intensity, and time-course persistence provide objective metrics for comparing experimental conditions and optimizing gene modulation strategies.
Why are replication requirements critical for cross-functional macrophage studies?
Replication ensures that observed effects of gene or microRNA modulation in peritoneal macrophages are robust and reproducible, facilitating reliable data sharing and decision-making across discovery and translational teams.
What statistical analysis capabilities are required before implementing lentiviral modulation in vivo?
Teams must be equipped to analyze infection rates, expression intensity, and time-course data using appropriate statistical methods to distinguish true biological effects from background variability in in vivo studies.
